Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05579431 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, First-in-human Study of VX-634
A Phase 1 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 127
- Enrollment target
NCT05579431 is a Phase 1 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 127 participants.
The verdict
NCT05579431, a Phase 1 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 127 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-634 at various doses.
Interventions
- DRUG Placebo
- DRUG VX-634
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2022-10-13 |
| Est. Completion | 2023-11-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05579431
The ClinicalTrials.gov registry entry for NCT05579431 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05579431 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05579431 about?
NCT05579431 is a clinical study titled "A Phase 1, First-in-human Study of VX-634". The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-634 at various doses.
What is the current status of trial NCT05579431?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 127 participants. The study started on 2022-10-13. Estimated completion is 2023-11-13.
What interventions are being tested in trial NCT05579431?
The interventions under investigation include: Placebo (DRUG), VX-634 (DRUG).
Who is sponsoring clinical trial NCT05579431?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.